

Metastatic

HER2 -

ER+ / PR+

Endocrine Sensitive

Endocrine Resistant

1st Line

2nd Line / 3rd Line

3rd Line +

None at this Time

No Prior Chemo

<= 1 Prior Chemo

Part 1A, Part 1D, Part 2A - (CCNE1 Amplified), Part 2B, Part 2D

If PIK3CA Altered

<= 2 Prior Chemo

<= 1 Prior Chemo

If PALB2 Mutation

3rd Line +

<= 1 Prior Chemo

BRS0128
[Phase Ib/II Umbrella Study of Multiple Treatment Combinations in Breast Cancer](#)

PI: Telli
Sponsor: F. Hoffmann-La Roche Ltd

BRS0144
[Phase Ib/II Umbrella Study of ARV-471 \(PF-07850327\) in Combo with other Anticancer Treatments in ER+ Advanced or Metastatic Breast Cancer Sub-Study A \(ARV-471 in Combination with Abemaciclib\)](#)

PI: Telli
Sponsor: Pfizer
1st Priority

BRS0145
[Phase Ib/II Umbrella Study of ARV-471 \(PF-07850327\) in Combo with other Anticancer Treatments in ER+ Advanced or Metastatic Breast Cancer Sub-Study B \(ARV-471 in Combination with Ribociclib\)](#)

PI: Telli
Sponsor: Pfizer
2nd Priority

VAR0243
Phase I/III Study to Evaluate the Safety Pharmacokinetics and Efficacy of BLU-222 as Single Agent and in Combination Therapy in Advanced Solid Tumors

PI: Telli
Sponsor: Blueprint Medicines Corporation

VAR0232
[LOXO-783 Monotherapy and in Combination with Anticancer Therapies in Advanced Breast Cancer and Other Solid Tumors with a PIK3CA H1047R Mutation](#)

PI: Chen
Sponsor: Loxo Oncology, Inc.

BRS0120
[Phase I/II ARV-471 in ER+/HER2- Locally Advanced or Metastatic Breast Cancer](#)

PI: Telli
Sponsor: Arvinas, Inc.

BRS0131
[Phase I/II IV Zotatfin \(eFT226\) in Selected Advanced Solid Tumor Malignancies](#)

PI: Caswell-Jin
Sponsor: eFFECTOR Therapeutics, Inc.

BRS0149
Phase III Sacituzumab Govitecan vs Treatment of Physician's Choice in Hormone Receptor-Positive (HR+) / Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-Low [IHC 1+, IHC2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer & Have Received Endocrine Therapy

PI: Riaz
Sponsor: Gilead Sciences, Inc.

BRS0126
[Phase II Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer](#)

PI: Telli
Sponsor: Stanford University

BRS0131
[Phase I/II IV Zotatfin \(eFT226\) in Selected Advanced Solid Tumor Malignancies](#)

PI: Caswell-Jin
Sponsor: eFFECTOR Therapeutics, Inc.

KEY

- Pending
- Open for Enrollment
- Observational Study

- Optional Path
- [Link](#) Trial Posting
- Enrollment on Hold

- Extension Study
- Immunotherapy